CagriSema 1.7 mg and 1.0 mg each cut bodyweight more than placebo in REDEFINE 9

In a phase 3b trial of adults with obesity or overweight and no diabetes, both lower CagriSema dose levels were superior to placebo for bodyweight loss at 68 weeks. At week 68, mean bodyweight fell by 20.7% (1.7 mg each), 21.0% (1.0 mg each) and 2.0% (pooled placebo), efficacy estimand. Most adverse events were mild or moderate and gastrointestinal. No deaths were reported. The trial was funded by Novo Nordisk, measured weight rather than clinical outcomes, and the abstract does not report a direct comparison of the two doses. Online version: https://www.diabesityrounds.com/a/cagrisema-1-7-mg-and-1-0-mg-each-cut-bodyweight-more-than-placebo-in-redefine-9

Authors

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2026-11-16
DOI
https://doi.org/10.5281/zenodo.24300392
Primary Topic
Pharmacology and Obesity Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

CagriSema 1.7 mg and 1.0 mg each cut bodyweight more than placebo in REDEFINE 9

Diabesity Rounds
Zenodo (CERN European Organization for Nuclear Research)
Pharmacology and Obesity Treatment
article

CagriSema 1.7 mg and 1.0 mg each cut bodyweight more than placebo in REDEFINE 9

Diabesity Rounds
article en

Abstract

In a phase 3b trial of adults with obesity or overweight and no diabetes, both lower CagriSema dose levels were superior to placebo for bodyweight loss at 68 weeks. At week 68, mean bodyweight fell by 20.7% (1.7 mg each), 21.0% (1.0 mg each) and 2.0% (pooled placebo), efficacy estimand. Most adverse events were mild or moderate and gastrointestinal. No deaths were reported. The trial was funded by Novo Nordisk, measured weight rather than clinical outcomes, and the abstract does not report a direct comparison of the two doses. Online version: https://www.diabesityrounds.com/a/cagrisema-1-7-mg-and-1-0-mg-each-cut-bodyweight-more-than-placebo-in-redefine-9

Zenodo (CERN European Organization for Nuclear Research)
Pharmacology and Obesity Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon